The short answer
Discuss ginkgo with your prescriber before using it with valproate, particularly for epilepsy. There is a concerning seizure report involving Depakote and several other products, and the European leaf monograph warns that further seizures in people with epilepsy cannot be excluded. Ginkgo has not been proven to lower valproate levels.
What this answer covers
Ginkgo biloba leaf preparations and an incompletely characterized supplement exposure in a case involving Depakote. Seed-toxin evidence is not assumed to establish leaf-extract effects.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- valproate
What the medication case reported
A man taking Depakote and Dilantin suffered a fatal breakthrough seizure. Drug levels at autopsy were low, and he had been using numerous supplements, including ginkgo. This is a serious signal, but the report cannot show that ginkgo alone caused the low levels or the seizure.
Leaf and seed evidence are different
The European monograph for ginkgo leaf preparations warns that further seizures in people with epilepsy cannot be excluded. This precaution does not require assuming that a leaf extract contains the same seizure-causing exposure as ginkgo seeds.
Why reduced effectiveness remains uncertain
The case authors proposed an effect on drug-metabolizing enzymes. The current valproate label describes those oxidation pathways as a minor part of valproate metabolism. The mechanism remains a hypothesis, and the case does not establish how ginkgo changes valproate levels.
Plan changes with the treating team
Avoid self-starting ginkgo for epilepsy while taking valproate; ask your prescriber to review it. No spacing interval has been shown to remove the concern. If seizures worsen, seek medical advice promptly, and do not abruptly stop valproate prescribed for epilepsy.
Evidence and practical considerations
Side effects & toxicity
A confounded seizure report involving Depakote and a leaf-specific epilepsy warning support caution, without establishing reduced valproate effectiveness or a timing-based solution.
- Exact scope
- Ginkgo biloba leaf preparations and an incompletely characterized supplement exposure in a case involving Depakote. Seed-toxin evidence is not assumed to establish leaf-extract effects. with Oral valproate active moiety; label evidence is from oral valproic acid capsules, with Depakote exposure identified separately where relevant.
- Medication form and route
- oral valproate; supplement route as specified in source and scope
- Timing or duration
- No safe co-use duration or protective spacing interval established.
What remains uncertain
- One case with multiple supplements and two anticonvulsants cannot isolate ginkgo, establish enzyme induction or quantify risk.
Factors that may matter: epilepsy; multiple supplements; other anticonvulsants.
Read the supporting source summaries
Source 1: current oral product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral valproic acid capsules.
Label warns of potentially fatal liver injury, especially during the first six months, and thrombocytopenia/coagulation abnormalities. It recommends baseline and follow-up liver and blood assessments. P450 oxidation is a minor metabolic pathway. Aspirin increased free valproate fraction in six pediatric patients; the study is aspirin-specific.
How this applies: Medication risk and identity context for RxCUI 40254 valproate; oral active-moiety bridge only.
Not a study of any of these botanical combinations. Active-moiety identity does not establish interchangeable doses, release kinetics or routes. Aspirin results do not establish salicin or methyl salicylate effects.
Source 2: fatal breakthrough-seizure case report
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 55-year-old man receiving Depakote and Dilantin and numerous supplements.
A fatal breakthrough seizure was accompanied by subtherapeutic anticonvulsant levels at autopsy. The authors proposed possible enzyme induction; the abstract found no evidence of noncompliance.
How this applies: Clinically relevant warning signal involving Depakote, with an active-moiety bridge to valproate; not proof of a specific leaf constituent or interaction magnitude.
Single fatal case with two anticonvulsants, many supplements and postmortem levels. Cannot isolate ginkgo or establish CYP2C19 induction as the cause. Seed neurotoxin discussion does not establish seed exposure in this case.
Source 3: EMA herbal monograph or public assessment summary
ema.europa.eu · Source check Sep 10, 2026
Population: People considering the specified herbal medicinal preparations.
In people with epilepsy, further seizures promoted by ginkgo preparations cannot be excluded.
How this applies: Leaf-specific epilepsy caution independent of extrapolation from ginkgo seed toxin.
Precaution, not a valproate interaction trial or quantified seizure frequency.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original sources checked and exact-pair evidence package prepared; no clinical review asserted. | |
| Research summary published |
Article revision: d53655b51577ef82
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.